| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CCNE |
| Entrez GeneID | 898 |
| clone | 5F8B4 |
| WB Predicted band size | 47kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CCNE1 (AA: 307-410) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与CCNE1抗体相关的文献摘要概览：
---
1. **"CCNE1 amplification is associated with poor prognosis and resistance to platinum-based chemotherapy in ovarian cancer"**
- **作者**: Etemadmoghadam, D., et al. (2010)
- **摘要**: 本研究通过免疫组化(使用CCNE1特异性抗体)和基因扩增分析，发现CCNE1蛋白过表达与卵巢癌患者预后不良及铂类化疗耐药显著相关，提示其作为潜在生物标志物的价值。
---
2. **"Proteolytic cleavage of cyclin E contributes to its oncogenic properties in breast cancer"**
- **作者**: Keyomarsi, K., et al. (2002)
- **摘要**: 利用CCNE1抗体进行Western blot分析，发现乳腺癌中低分子量cyclin E的异常切割形式与肿瘤侵袭性增强及患者生存率降低相关，揭示了其作为治疗靶点的潜力。
---
3. **"CCNE1 overexpression enhances sensitivity to PARP inhibitors in DNA repair-deficient tumors"**
- **作者**: Scaltriti, M., et al. (2011)
- **摘要**: 通过抗体检测CCNE1蛋白表达，研究发现CCNE1过表达的肿瘤对PARP抑制剂敏感性增加，尤其在DNA修复缺陷型癌症中，为精准治疗策略提供了依据。
---
这些文献均涉及CCNE1抗体的实验应用(如免疫组化、Western blot)，并探讨了CCNE1在癌症中的功能及临床意义。如需具体文章链接或补充，可进一步检索PubMed或期刊数据库。
CCNE1 (Cyclin E1) is a key regulatory protein involved in cell cycle progression, primarily governing the transition from the G1 phase to the S phase. It forms a complex with cyclin-dependent kinase 2 (CDK2), facilitating phosphorylation of retinoblastoma (Rb) protein, which releases E2F transcription factors to drive DNA replication. Overexpression of CCNE1 is frequently observed in various cancers, including ovarian, breast, and endometrial cancers, and is associated with genomic instability, tumor aggressiveness, and poor prognosis.
CCNE1 antibodies are critical tools for detecting and quantifying CCNE1 expression in research and diagnostics. These antibodies enable the study of cell cycle dysregulation in cancer, assessment of CCNE1 as a potential biomarker, and evaluation of therapeutic strategies targeting cyclin-CDK complexes. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF).
Recent studies highlight CCNE1 amplification as a resistance mechanism to CDK4/6 inhibitors, driving interest in CCNE1-targeted therapies, such as CDK2 inhibitors or synthetic lethality approaches. However, challenges remain in developing specific inhibitors due to structural similarities among cyclins. Validated CCNE1 antibodies are essential for advancing these investigations, emphasizing the need for high specificity and reproducibility in experimental models and clinical samples.
×
